Crown Bioscience is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology.
San Diego, California
- Tweets 10,154
- Following 555
- Followers 10,951
- Likes 713
AML can be incredibly difficult to treat. We’re working hard to change that.
With a team of dedicated scientists at the helm, Crown Bioscience leverages state-of-the-art preclinical tools to supercharge your AML research and drug development needs.
okt.to/KA290q
1
61
As one of Europe’s largest biotech partnering events, BIOSPAIN brings together companies and delegates from around the world.
If you’ll be there, connect with Karolina to arrange a conversation or schedule a meeting in advance.
okt.to/xQhEXF
1
2
55
In this on-demand webinar, Dr. Xiaolong Tu presents a systematic, tiered nonclinical DMPK Tox strategy that addresses these challenges head-on.
Watch now: okt.to/lq10NP
63
In this 30-minute expert-led webinar, we explore why understanding the complexity of the tumor microenvironment is critical for advancing therapies in hematologic cancers.
Watch now: okt.to/CGuxcQ
62
A new study from our team integrates transcriptomic, proteomic, and genomic data from more than 10,000 primary tumors against roughly 4,000 preclinical models spanning cell lines, PDXs, PDOs, and PDXOs across 17–37 tumor types depending on the data layer: okt.to/FLGyuo.
64
Crown Bioscience retweeted
本日より第85回日本癌学会に出展しております。Crown Bioscienceの多彩な前臨床サービスをがん種毎の統合型ソリューションとしてご紹介しています。日本癌学会にお越しの際はぜひCrown Bioscienceのブースにお立ち寄りください！
#オンコロジー #イムノオンコロジー #JCA @crownbioscience
2
5
149
In this blog, we explain why biomarker-guided strategies and robust AML models are central to advancing therapeutic development.
Read now: okt.to/LbIWNc
63
Join Crown Bioscience on October 20 at 11 AM EST for our webinar, Advancing Breast Cancer Drug Development with Translational Models and Biomarker-Driven Strategies.
Register now. okt.to/8mhjEr
74
How can integrated PDX/PDXO platforms enable more effective ADC therapies to overcome clinical resistance?
See the science for yourself: okt.to/BhOIad
78
This #WorldCleanupDay, we’re continuing to look for practical ways to make science more sustainable, without compromising quality, safety, or scientific rigor. Learn more about our approach to sustainability: okt.to/MFCgoO
60
We hosted our symposium at the Museum of Science in Boston, for a day filled with engaging discussions, valuable networking, & the chance to experience our AI-powered scientific guide!
Thank you to all the presenters and participants who contributed to the success of the event.
1
2
95
Explore our monthly Customer Satisfaction Report, showcasing our commitment to authenticity and transparency.
See the data: okt.to/filRvk
56
Our AACR 2026 Poster shows how tracking the Drug-to-Antibody Ratio with a robust ADC testing platform provides data that’s critical for de-risking drug development.
Discover how specific linker types and payloads influence DAR across different species: okt.to/Yq7Anh
65
From working alongside a productive team to continually learning something new, Roxane Napoli, Senior Director, Marketing Communications and Operations shares what first attracted her to Crown Bioscience: the people and the teams behind the science.
88
⏰Just two days to go! Don't miss our webinar exploring how an integrated nonclinical strategy can help advance ADC programs from discovery to IND, live on September 16 at 11 AM EST.
Register now.
okt.to/0gQxVX
1
97
Join us on September 16 for an afternoon of cutting-edge science, translational research insights and networking with fellow researchers and drug discovery leaders.
okt.to/woj14O
1
1
59
Our AACR 2026 Poster demonstrates how organoid fibroblast co-culture systems, combined with high-content imaging (HCI), improve the assessment of tumor killing, immune infiltration and resistance mechanisms.
okt.to/AQkdG0
67
Here, Prof. Thomas Hartung, Director of the Johns Hopkins Center for Alternatives to Animal Testing, unpacks how the FDA Modernization Act, AI, and next-generation in vitro systems are transforming drug discovery.
Catch the full conversation: okt.to/Pb2AKI
97
📄Our latest research represents one of the largest multi-omic comparisons of preclinical cancer models ever conducted.
Read the full open-access paper in JCI Insight: okt.to/kaLtIe
46
From patient-derived organoids to AI-driven modeling, explore how NAMs can support stronger translational decisions and robust weight-of-evidence strategies for IND submissions: okt.to/675DsQ
56